Small Caps To Watch

   
   
   
   
   

 

 

Small Caps Of The Day - CCC, ITUS

Thursday 9/21/17-  Pre-market movers. CCC, $21.35, Up 61 %. ITUS, $2.14, Up 10%. 

Calgon Carbon Corporation (CCC) and Kuraray Co., Ltd. (TYO:3405) announced today that their respective Boards of Directors have unanimously approved, and the parties have entered into, a definitive merger agreement under which Kuraray will acquire Calgon Carbon for $21.50 per share in cash, which equates to an equity value of approximately $1.1 billion, and a transaction value in excess of $1.3 billion, including Calgon Carbon’s net indebtedness.

What They Do: Calgon Carbon Corporation is a global leader in innovative solutions, high quality products and reliable services designed to protect human health and the environment from harmful contaminants in water and air.

ITUS Corporation (ITUS), Today provides a corporate update before its Annual Meeting of Stockholders to be held on September 22, 2017.

ITUS's wholly owned subsidiary Anixa Diagnostics, recently renewed its research agreement with The Wistar Institute for continued development of Cchek™, its early cancer detection technology. Dr. Amit Kumar, President and CEO of ITUS stated, "We continue to make progress in our R&D efforts as we work with our partners, MD Anderson, U. Pennsylvania's Abramson Cancer Center, Delaware Valley Urology, Virtua Hospitals, and others. Cchek™, which has demonstrated 91% sensitivity and specificity in a preliminary study, continues to perform at that level or better."

ITUS also recently announced the issuance of US Patent 9,739,783 covering its technology for cancer detection. This ITUS patent was issued to inventors Dr. Amit Kumar and John Roop, the CEO and VP of Engineering, respectively, of ITUS Corp.

What They Do: ITUS, a cancer-focused biotechnology company, through its wholly owned subsidiary, Anixa Diagnostics Corporation, is developing the Cchek™ platform, a series of non-invasive blood tests for the early detection of solid tumor based cancers, which is based on the body's immunological response to the presence of a malignancy.

 


About SmallCapReview

Features available at SmallCapReview.com include in-depth profiles of select Small-Cap/Penny Stocks as well as the most comprehensive and up to date news available on the small-cap market.

No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Nothing within our site should be construed as an offer or solicitation to buy or sell products or securities. The companies we profile may lack an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. 

Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play.